Aptinyx Reports Third Quarter 2019 Financial Results and Highlights by Seini Moimoi | Nov 12, 2019 | Portfolio News
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions by Seini Moimoi | Nov 12, 2019 | Portfolio News
Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results by Seini Moimoi | Nov 12, 2019 | Portfolio News
89bio Announces Pricing of Upsized Initial Public Offering by Seini Moimoi | Nov 11, 2019 | Portfolio News
Akebia Announces Positive 52-week Efficacy and Safety Data for Vadadustat from Two Pivotal Phase 3 Studies in Japanese Patients with Anemia Due to Chronic Kidney Disease by Seini Moimoi | Nov 9, 2019 | Portfolio News
